Imozop

Zopiclone, the active ingredient in Imozop, is a cyclopyrrolone (non‑benzodiazepine hypnotic) presented as an oral tablet for oral use. It is indicated for the short‑term treatment of insomnia in adults who have difficulty falling or staying asleep.

GNH USA supplies Imozop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Zopiclone acts on the central nervous system to treat sleep disorders, particularly insomnia.

- Insomnia (difficulty initiating sleep): helps patients fall asleep more quickly. - Insomnia (difficulty maintaining sleep): reduces nighttime awakenings and improves sleep continuity. - Transient sleep disturbance: provides temporary relief for short‑term sleep disruption.

Common Side Effects: - Drowsiness: feeling unusually sleepy during the day. - Dry mouth: reduced salivary flow causing discomfort. - Bitter or unpleasant taste. - Headache: mild to moderate cranial pain. - Dizziness: sensation of light‑headedness or unsteadiness. - Nausea: mild stomach upset.

Serious or Rare Side Effects: - Complex sleep behaviours: activities such as sleepwalking or driving while not fully awake. - Allergic reactions: rash, itching, swelling, or difficulty breathing. - Depression or mood changes: worsening depressive symptoms. - Memory impairment: difficulty recalling events after waking.

Before prescribing Zopiclone, clinicians should consider several safety factors.

- Assess renal function: adjust use in severe impairment. - Avoid alcohol: concurrent use may increase sedation and respiratory depression. - Monitor for dependence: limit duration to the shortest effective period. - Caution in elderly: increased sensitivity to sedative effects and risk of falls. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Zopiclone may interact with other substances that affect the central nervous system or its metabolism.

Major Interactions (Avoid): - Concomitant use with other CNS depressants (e.g., opioids, benzodiazepines): risk of profound sedation. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations. - Alcohol: additive CNS depression and impaired coordination.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Antidepressants (e.g., fluoxetine, sertraline): may enhance sedative properties. - Antihistamines (e.g., diphenhydramine): may increase drowsiness and impair alertness.